Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Canc…

BD200 demonstrated superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop-2 or ...

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

Peptide Drug Conjugates (PDCs) present major growth opportunities in oncology and beyond, triggered by innovations in peptide chemistry, enhanced targeting, and reduced systemic toxicity. With a ...

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data ...
PharmiWeb

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline –– Industry Leading ADC Platform That Includes its Clinically-Validated Tubutecan ...
Business Wire

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

LAUSANNE, Switzerland & SUWON-SI GYEONGGI-DO, South Korea--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s ...
Morningstar

Ellipses In-Licenses First-in-Class B7H3 Antibody Drug Conjugate From China

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence ...
KTLA

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an ...
BioWorld

Preclinical evaluation of first-in-class CX-2051 antibody-drug conjugate

Epithelial cell adhesion molecule (EpCAM) is involved in cancer cell invasion while it acts as a negative regulator of adhesion. EpCAM is overexpressed in several cancer types, such as colorectal, ...
Eagle-Tribune

Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate ...

Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study initiation follows positive ...
BioWorld

First-in-class drug-Fc conjugate shows efficacy in preclinical cancer models

BioWorld - Saturday, September 20, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » First-in-class drug-Fc conjugate shows ...